Comparative Pharmacology
Head-to-head clinical analysis: FENOFIBRIC ACID versus FENOGLIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOFIBRIC ACID versus FENOGLIDE.
FENOFIBRIC ACID vs FENOGLIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenofibric acid is a peroxisome proliferator-activated receptor alpha (PPARα) agonist that increases lipolysis and clearance of triglyceride-rich lipoproteins and reduces apolipoprotein C-III production, leading to decreased triglycerides and increased HDL cholesterol.
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma, reduces hepatic production of VLDL, and increases HDL cholesterol.
135 mg orally once daily
160 mg orally once daily, taken with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 15-25 h) for fenofibric acid, supporting once-daily dosing. In renal impairment, half-life may be prolonged.
Clinical Note
moderateFenofibric acid + Cyclosporine
"Fenofibric acid may increase the nephrotoxic activities of Cyclosporine."
Clinical Note
moderateFenofibric acid + Raltegravir
"Fenofibric acid may increase the myopathic rhabdomyolysis activities of Raltegravir."
Clinical Note
moderateFenofibric acid + Chenodeoxycholic acid
"The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Fenofibric acid."
Clinical Note
moderateFenofibric acid + Ursodeoxycholic acid
The terminal elimination half-life of fenofibric acid is approximately 20 hours (range 15-25 hours). This long half-life allows once-daily dosing. Steady-state is reached within approximately 5 days.
Primarily renal as unchanged drug and glucuronide conjugate (approximately 60-70% of dose); remainder eliminated via biliary/fecal routes (~25%).
Fenoglide (fenofibrate) is primarily excreted in urine as fenofibric acid and its glucuronide conjugate, accounting for approximately 60-70% of the dose. About 20-25% is eliminated in feces via biliary excretion. Renal excretion is the major route.
Category C
Category C
Antilipemic
Antilipemic
"The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Fenofibric acid."